Veteran executive David Gill joins Telix (NASDAQ: TLX) board as NED
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Telix Pharmaceuticals Limited has appointed experienced life sciences executive David Gill as a Non-Executive Director as part of its board expansion and succession planning. His appointment is effective May 11, 2026, subject to grant of an Australian Director Identification number.
Gill is expected to become Chair in due course, succeeding Interim Chair Dr. Mark Nelson, who will remain on the board as a Non-Executive Director. Telix also announced that Genevieve Ryan resigned as Company Secretary effective April 2, 2026, with Shomalin Naidoo appointed interim Company Secretary and primary ASX Listing Rule contact from the same date.
Positive
- None.
Negative
- None.
Key Figures
Board appointment effective date: May 11, 2026
Company Secretary change date: April 2, 2026
Industry experience: Over 35 years
3 metrics
Board appointment effective date
May 11, 2026
Effective date of David Gill’s Non-Executive Director role
Company Secretary change date
April 2, 2026
Effective date of resignation of Genevieve Ryan and interim appointment of Shomalin Naidoo
Industry experience
Over 35 years
David Gill’s senior management and financial leadership experience in life sciences
Key Terms
Non-Executive Director, Company Secretary, succession planning, radiopharmaceuticals, +1 more
5 terms
Non-Executive Director financial
"Telix Appoints David Gill as Non-Executive Director"
A non-executive director is a member of a company’s board who does not work for the company day-to-day but provides independent oversight, strategic guidance and checks on management. For investors, they matter because they act like an impartial referee or outside advisor, helping ensure decisions protect shareholder interests, reduce risks of poor governance, and add credibility to financial reporting and long-term strategy.
Company Secretary financial
"The Company also advises that Genevieve Ryan has tendered her resignation as Company Secretary"
succession planning financial
"as part of Board expansion and succession planning"
A company’s plan for identifying and preparing people to take over key roles when leaders leave, retire, or are unable to work. Like a sports team’s bench and playbook, it ensures someone ready can step in quickly so operations, strategy and investor confidence aren’t disrupted; investors watch it because solid succession planning reduces the risk of sudden leadership gaps that can hurt performance and stock value.
radiopharmaceuticals medical
"focused on the development and commercialization of radiopharmaceuticals"
Radiopharmaceuticals are medicines that carry tiny amounts of radioactive material to help doctors see or treat disease inside the body, acting like a tracer dye for imaging or a microscopic guided missile for targeted therapy. They matter to investors because their safety, regulatory approval, production complexity, short shelf life and hospital reimbursement determine how quickly they can reach patients and generate revenue, affecting a company’s sales potential and risk profile.
forward-looking statements regulatory
"This announcement may contain forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of April, 2026
Commission File Number: 001-42128
Telix Pharmaceuticals Limited
(Translation of registrant’s name into English)
55 Flemington Road
North Melbourne, Victoria 3051, Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On April 2, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement with the Australian Securities Exchange titled “Telix Appoints David Gill as Non-Executive Director,” a copy of which is attached to this Form 6-K as Exhibit 99.1.
The information contained in this Form 6-K is incorporated by reference into our Registration Statement on Form F-3ASR (File No. 333-293611) and Registration Statement on Form S-8 (File No. 333-283917).
|
99.1
|
Press release – April 2, 2026
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Telix Pharmaceuticals Limited
|
|
|
|
|
|
|
Date: April 2, 2026
|
By:
|
/s/ Christian Krautkramer
|
|
|
|
Name: Christian Krautkramer
|
|
|
|
Title: Group General Counsel
|
Telix Pharmaceuticals LimitedACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia
ASX ANNOUNCEMENT
Telix Appoints David Gill as Non-Executive Director
Melbourne (Australia) and Indianapolis, IN (U.S.) – April 2, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 20261. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as a NED.
Mr. Gill is a life sciences executive with over 35 years’ experience in senior general management and financial leadership roles across commercial and clinical-stage biopharmaceutical (including radiopharmaceuticals) and medical device companies. He currently serves on the boards of Evolus, Inc. (NASDAQ: EOLS), Allucent LLC, Bridge to Life Ltd, RapidPulse Inc. and huMannity Medtec (formerly Alfred Mann Foundation), and was until recently a board member of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), Strongbridge Biopharma plc (NASDAQ: SBBP), Alpha Source Inc, Healthtronics, Inc, and Perimetrics, LLC.
Mr. Gill brings deep expertise in capital markets, scaling businesses, governance and corporate turn-around strategy and has served as Chief Financial Officer or President of multiple publicly traded companies, including EndoChoice Holdings, Inc. (NYSE: GI, acquired by Boston Scientific), INC Research (NASDAQ: INCR, now Syneos Health), and CTI Molecular Imaging (NASDAQ: CTMI, acquired by Siemens). He holds a B.S. in Accounting from Wake Forest University and an MBA from Emory University.
Telix Interim Chair, Mark Nelson, commented, “We are pleased to welcome David to the Board, where his strong financial expertise and deep knowledge of U.S. capital markets will be highly valuable. We intend to further strengthen the Board through additional appointments aligned with our growth trajectory and governance needs as a dual-listed company.”
Change of Company Secretary
The Company also advises that Genevieve Ryan has tendered her resignation as Company Secretary, effective today, April 2, 2026. The Company and Board thank Ms. Ryan for her valuable contributions and service to the organization since December 2022 and wish her well in future endeavors.
Mr. Shomalin Naidoo has been appointed Company Secretary effective today, April 2, 2026, on an interim basis, while the Company recruits a permanent Company Secretary. Mr. Naidoo will be the primary person responsible for communications with the ASX under ASX Listing Rule 12.6 in relation to Listing Rule matters.
About Telix Pharmaceuticals Limited
Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix
is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
|
Telix Investor Relations (Global)
Ms. Kyahn Williamson
SVP Investor Relations and Corporate Communications
kyahn.williamson@telixpharma.com
|
Telix Investor Relations (U.S.)
Ms. Annie Kasparian
Director Investor Relations and Corporate Communications
annie.kasparian@telixpharma.com
|
Telix Investor Relations (Australia)
Ms. Charlene Jaw
Associate Director Investor
Relations
charlene.jaw@telixpharma.com
|
|
Media Contact
Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com
This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
1 Subject to grant of Australian Director Identification number.
2
FAQ
What did Telix Pharmaceuticals (TLX) announce in its April 2026 6-K?
Telix Pharmaceuticals announced the appointment of David Gill as a new Non-Executive Director, with an expected transition to Chair, and reported a change in Company Secretary, with Genevieve Ryan resigning and Shomalin Naidoo taking over on an interim basis.
Who is David Gill and what role will he have at Telix (TLX)?
David Gill is a life sciences executive with over 35 years’ senior management and financial leadership experience. He has been appointed as a Non-Executive Director effective May 11, 2026, and is expected to be appointed Chair of Telix’s Board in due course.
When does David Gill’s appointment to the Telix (TLX) board become effective?
David Gill’s appointment as a Non-Executive Director becomes effective on May 11, 2026, subject to the grant of an Australian Director Identification number. He is then expected to be appointed Chair, succeeding Interim Chair Dr. Mark Nelson, who will remain on the board.
What board leadership changes did Telix (TLX) signal regarding its Chair role?
Telix indicated that David Gill is expected to be appointed Chair of the Board in due course, succeeding Interim Chair Dr. Mark Nelson. Dr. Nelson will remain on the Board as a Non-Executive Director, supporting continuity while leadership responsibilities transition over time.
What change did Telix (TLX) make to the Company Secretary position?
Telix reported that Company Secretary Genevieve Ryan resigned effective April 2, 2026. The company appointed Shomalin Naidoo as Company Secretary on an interim basis from the same date, and he will be the primary contact for ASX communications under Listing Rule 12.6.
What is Telix Pharmaceuticals’ (TLX) core business focus and global presence?
Telix is a global biopharmaceutical company focused on developing and commercializing radiopharmaceuticals to address unmet medical needs in oncology and rare diseases. It is headquartered in Melbourne, with operations in the U.S., U.K., Brazil, Canada, Europe and Japan, and dual listings on ASX and Nasdaq.